Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BOLD
Upturn stock ratingUpturn stock rating

Boundless Bio, Inc. Common Stock (BOLD)

Upturn stock ratingUpturn stock rating
$1.56
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

05/22/2025: BOLD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -24.09%
Avg. Invested days 5
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 05/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.16M USD
Price to earnings Ratio 0.22
1Y Target Price 15
Price to earnings Ratio 0.22
1Y Target Price 15
Volume (30-day avg) 54308
Beta -
52 Weeks Range 1.06 - 12.26
Updated Date 05/22/2025
52 Weeks Range 1.06 - 12.26
Updated Date 05/22/2025
Dividends yield (FY) -
Basic EPS (TTM) 7.71

Earnings Date

Report Date 2025-05-09
When -
Estimate -0.735
Actual -0.71

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -29.89%
Return on Equity (TTM) -54.06%

Valuation

Trailing PE 0.22
Forward PE -
Enterprise Value -52518886
Price to Sales(TTM) -
Enterprise Value -52518886
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 22385600
Shares Floating 14281523
Shares Outstanding 22385600
Shares Floating 14281523
Percent Insiders 11.39
Percent Institutions 70.33

Analyst Ratings

Rating 4
Target Price 15
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Boundless Bio, Inc. Common Stock

Company Overview

overview logo History and Background

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing innovative therapies targeting extrachromosomal DNA (ecDNA) biology. Founded in 2018, the company is based in San Diego, California.

business area logo Core Business Areas

  • ecDNA-Directed Therapies: Develop therapies that target ecDNA, a circular form of DNA found in cancer cells that drives tumor growth and resistance to treatment.

leadership logo Leadership and Structure

The company is led by a team of experienced biotechnology executives and scientists. Details regarding the exact leadership team and organizational structure can be found on their official website or regulatory filings.

Top Products and Market Share

overview logo Key Offerings

  • BBI-350: BBI-350 is a Chk1 inhibitor designed to selectively kill cancer cells harboring ecDNA. It is currently in clinical trials. Specific market share or revenue data is not yet available as it is still under development. Competitors include other companies developing Chk1 inhibitors and other novel cancer therapies, such as Merck, Eli Lilly, and AstraZeneca.

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and rapidly growing market driven by an increasing incidence of cancer and advancements in treatment. The development of targeted therapies, including those focused on specific genetic drivers of cancer, is a key trend.

Positioning

Boundless Bio is positioned as a leader in the emerging field of ecDNA-directed therapies. Its focus on a novel target differentiates it from many other oncology companies.

Total Addressable Market (TAM)

The TAM for ecDNA-directed therapies is potentially large, as ecDNA is found in many types of cancer. An estimate would depend on the clinical success of ecDNA-targeting compounds, but could reasonably be in the tens of billions of dollars if successful. Boundless Bio is positioned to capture a significant portion of this TAM if its therapies prove effective.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic target (ecDNA)
  • Experienced management team
  • Strong intellectual property position
  • Clinical-stage pipeline

Weaknesses

  • Early stage of development
  • High risk of clinical trial failure
  • Reliance on single therapeutic approach
  • Limited financial resources compared to larger pharma companies

Opportunities

  • Expansion of pipeline to other ecDNA-driven cancers
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Potential for breakthrough therapy designation

Threats

  • Clinical trial failures
  • Competition from other oncology companies
  • Regulatory hurdles
  • Changes in the competitive landscape of oncology treatments

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • LLY
  • AZN

Competitive Landscape

Boundless Bio's competitive advantage lies in its novel approach to targeting ecDNA. However, it faces competition from larger pharmaceutical companies with more established oncology portfolios.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Historical growth is measured by the expansion of their pipeline and clinical development milestones.

Future Projections: Future growth depends on clinical trial success and securing additional funding. Analyst estimates are available from various financial data providers.

Recent Initiatives: Recent initiatives include advancing BBI-350 through clinical trials and exploring additional ecDNA targets.

Summary

Boundless Bio is a clinical-stage biotechnology company focused on a novel target, ecDNA. Its innovative approach offers potential in the oncology space, but it faces significant risks associated with clinical development. The company's success hinges on positive clinical trial results and securing sufficient funding. They need to monitor competition and adapt to changes in the oncology treatment landscape.

Similar Companies

AZNratingrating

AstraZeneca PLC ADR

$69.95
Large-Cap Stock
0%
PASS

AZNratingrating

AstraZeneca PLC ADR

$69.95
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$715.2
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$715.2
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.84
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.84
Large-Cap Stock
0%
PASS

Sources and Disclaimers

Data Sources:

  • Boundless Bio's website
  • SEC filings (10-K, 10-Q)
  • Analyst reports
  • Press releases

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. The AI-based rating is based on publicly available information and is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Boundless Bio, Inc. Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2024-03-28
CEO, President & Director Mr. Zachary Hornby
Sector Healthcare
Industry Biotechnology
Full time employees 64
Full time employees 64

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.